The three criteria as discussed above, including the major drug response phenotype (P/A/D), the presence or absence of critical target, and the presence or absence of the set of critical genomic determinant, enabled us to classify the heterogeneous drug responses of the 45 p53 network subtypes from the 83 human cancer cell lines into eight distinct response groups (Fig. 3c, d). This evidence concerns the gene TP53 and cancer.